The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX(®) Recurrence Score in ER-Positive Invasive Breast Cancers

We assessed mRNA and protein expression levels of the ZN217 oncogene in 17 clinical FFPE ER-positive invasive breast cancer specimens with known (low or high) Oncotype DX(®) Recurrence Scores. This study shows that mRNA or nuclear protein levels of the ZNF217 significantly correlate with Oncotype DX...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Pascale A., Loudig, Olivier, Liu, Christina, Albanese, Joseph, Fineberg, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6546897/
https://www.ncbi.nlm.nih.gov/pubmed/31191299
http://dx.doi.org/10.3389/fphar.2019.00524
_version_ 1783423598868824064
author Cohen, Pascale A.
Loudig, Olivier
Liu, Christina
Albanese, Joseph
Fineberg, Susan
author_facet Cohen, Pascale A.
Loudig, Olivier
Liu, Christina
Albanese, Joseph
Fineberg, Susan
author_sort Cohen, Pascale A.
collection PubMed
description We assessed mRNA and protein expression levels of the ZN217 oncogene in 17 clinical FFPE ER-positive invasive breast cancer specimens with known (low or high) Oncotype DX(®) Recurrence Scores. This study shows that mRNA or nuclear protein levels of the ZNF217 significantly correlate with Oncotype DX(®) Recurrence Score.
format Online
Article
Text
id pubmed-6546897
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-65468972019-06-12 The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX(®) Recurrence Score in ER-Positive Invasive Breast Cancers Cohen, Pascale A. Loudig, Olivier Liu, Christina Albanese, Joseph Fineberg, Susan Front Pharmacol Pharmacology We assessed mRNA and protein expression levels of the ZN217 oncogene in 17 clinical FFPE ER-positive invasive breast cancer specimens with known (low or high) Oncotype DX(®) Recurrence Scores. This study shows that mRNA or nuclear protein levels of the ZNF217 significantly correlate with Oncotype DX(®) Recurrence Score. Frontiers Media S.A. 2019-05-28 /pmc/articles/PMC6546897/ /pubmed/31191299 http://dx.doi.org/10.3389/fphar.2019.00524 Text en Copyright © 2019 Cohen, Loudig, Liu, Albanese and Fineberg. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Cohen, Pascale A.
Loudig, Olivier
Liu, Christina
Albanese, Joseph
Fineberg, Susan
The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX(®) Recurrence Score in ER-Positive Invasive Breast Cancers
title The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX(®) Recurrence Score in ER-Positive Invasive Breast Cancers
title_full The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX(®) Recurrence Score in ER-Positive Invasive Breast Cancers
title_fullStr The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX(®) Recurrence Score in ER-Positive Invasive Breast Cancers
title_full_unstemmed The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX(®) Recurrence Score in ER-Positive Invasive Breast Cancers
title_short The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX(®) Recurrence Score in ER-Positive Invasive Breast Cancers
title_sort znf217 biomarker predicts low- and high-risk oncotype dx(®) recurrence score in er-positive invasive breast cancers
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6546897/
https://www.ncbi.nlm.nih.gov/pubmed/31191299
http://dx.doi.org/10.3389/fphar.2019.00524
work_keys_str_mv AT cohenpascalea theznf217biomarkerpredictslowandhighriskoncotypedxrecurrencescoreinerpositiveinvasivebreastcancers
AT loudigolivier theznf217biomarkerpredictslowandhighriskoncotypedxrecurrencescoreinerpositiveinvasivebreastcancers
AT liuchristina theznf217biomarkerpredictslowandhighriskoncotypedxrecurrencescoreinerpositiveinvasivebreastcancers
AT albanesejoseph theznf217biomarkerpredictslowandhighriskoncotypedxrecurrencescoreinerpositiveinvasivebreastcancers
AT finebergsusan theznf217biomarkerpredictslowandhighriskoncotypedxrecurrencescoreinerpositiveinvasivebreastcancers
AT cohenpascalea znf217biomarkerpredictslowandhighriskoncotypedxrecurrencescoreinerpositiveinvasivebreastcancers
AT loudigolivier znf217biomarkerpredictslowandhighriskoncotypedxrecurrencescoreinerpositiveinvasivebreastcancers
AT liuchristina znf217biomarkerpredictslowandhighriskoncotypedxrecurrencescoreinerpositiveinvasivebreastcancers
AT albanesejoseph znf217biomarkerpredictslowandhighriskoncotypedxrecurrencescoreinerpositiveinvasivebreastcancers
AT finebergsusan znf217biomarkerpredictslowandhighriskoncotypedxrecurrencescoreinerpositiveinvasivebreastcancers

Ejemplares similares